1. Home
  2. DLNG vs IPHA Comparison

DLNG vs IPHA Comparison

Compare DLNG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

N/A

Current Price

$3.18

Market Cap

140.8M

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.39

Market Cap

167.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLNG
IPHA
Founded
2013
1999
Country
Greece
France
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.8M
167.6M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
DLNG
IPHA
Price
$3.18
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
★ 61.2K
24.3K
Earning Date
11-19-2026
09-17-2026
Dividend Yield
★ 6.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
$1.10
$143.06
P/E Ratio
$3.04
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$1.17
52 Week High
$4.45
$2.71

Technical Indicators

Market Signals
Indicator
DLNG
IPHA
Relative Strength Index (RSI) 27.02 36.03
Support Level N/A $1.38
Resistance Level $3.96 $1.59
Average True Range (ATR) 0.09 0.07
MACD -0.01 0.01
Stochastic Oscillator 11.96 4.55

Price Performance

Historical Comparison
DLNG
IPHA

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: